Monoclonal Antibodies No Better Than Placebo for Early Parki

The monoclonal antibodies cinpanemab and prasinezumab show almost no benefit for early Parkinson disease.

Related Keywords

Toronto , Ontario , Canada , Switzerland , Gennaro Pagano , Prothena Biosciences , Anthonye Lang , Roche Innovation Center Basel , University Of Toronto , Movement Disorder , Healthday News , New England Journal , Movement Disorder Society Sponsored , Unified Parkinson , Disease Rating Scale ,